The results of glaucoma drainage tube surgery in patients with diabetes

Aim. To compare the effectiveness of "Glautex" drainage and the Ahmed valve for the treatment of secondary neovascular glaucoma in patients with diabetes.

Material and methods. We observed 28 eyes with neovascular glaucoma in 28 patients with proliferative diabetic retinopathy. The mean age of patients was 56.61 ± 1.43 years (range: 40–65). There were 11 males and 17 females. Patients were divided into two groups based on the drainage device used. The first group included 13 patients (13 eyes) for whom "Glautex" drainage was used, while the second group included 15 patients for whom the Ahmed valve model FP7 (New World Medical Inc., USA) was used.

Results. The absolute hypotensive effect [normalization of intraocular pressure (IOP) without the use of drugs] 1 year after surgery was 46.1% (6/13) in group I and 60% (9/15) in group II. The relative hypotensive effect (normalization of IOP during treatment with glaucoma drugs) 1 year after surgery was 53.8% (7/13) in group I and 80% (12/15) in group II. Hyphema in the early postoperative period was observed in 30.7% (4/13) and 26.6% (4/15) of patients in groups I and II, respectively. Hypotension with choroid detachment was observed in 23.1% (3/13) of group I patients and 13.3% (2/15) of group II patients. Migration of the tube to the scleral layers occurred after implantation of the Ahmed valve in 6.6% (1/15) of patients.

Conclusion. Comparative analysis of the outcomes of surgical treatment of secondary neovascular glaucoma in patients with diabetes showed that the most effective method to lower IOP was implantation of an Ahmed valve. The valve preserved visual function during the 1-year follow-up period and resulted in failed outcomes in only 20% of patients. The hypotensive effect of sinus trabeculectomy was observed in 53.8% of patients with "Glautex" drainage. There was a progressive decrease in visual function and the need for reintervention in 46.1% of group 1 patients.

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. The British Journal of Ophthalmology. 2006;90(3):262-267. doi: 10.1136/bjo.2005.081224

2. Каспаров A.A., Маложен С.А., Труфанов C.B. Применение амниотической мембраны в хирургическом лечении глауком. — Материалы Юбилейной Всероссийской научно практической конференции. — Москва, 2000. — Ч.1. — С. 134-136. [Kasparov AA, Malozhen SA, Trufanov CB. Primenenie amnioticheskoy membrany v khirurgicheskom lechenii glaukom. Proceedings of Anniversary Russian Scientific Conference. Moscow; 2000. Chapter 1. P. 134-136. (In Russ)].

3. Akova Y, Bulut S, Dabil H, Duman S. Late Bleb-Related Endophthalmitis after Trabeculectomy with Mitomycin C. Ophthalmic Surg Lasers. 1999; 30: 146-151. doi: 10.3928/1542-8877-19990201-12

4. Sivak-Callcott JA, O’Day DM, Gass JDM, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108(10):1767-1776. doi: 10.1016/s0161-6420(01)00775-8

5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2010;21(2):112-117. doi: 10.1097/ICU.0b013e3283360aad

6. Pokroy R, Greenwald Y, Pollack A, et al. Visual Loss After Transscleral Diode Laser Cyclophotocoagulation for Primary Open-Angle and Neovascular Glaucoma. Ophthalmic Surgery, Lasers, and Imaging. 2008;39(1):22-29. doi: 10.3928/15428877-20080101-09

7. Еричев В.П., Ермолаев А.П. Эффективность и безопасность дренажной хирургии при неоваскулярной глаукоме. Глаукома: реальность и перспективы. Сб. науч. статей. – Москва; 2008. [ErichevVP, Ermolaev AP. Effektivnost’ i bezopasnost’ drenazhnoy khirurgii pri neovaskulyarnoy glaukome. Glaukoma: real’nost’ i perspektivy. Sbornik nauchyh. statey. Moscow; 2008. (In Russ)].

8. Липатов Д.В., Чистяков Т.А. Использование клапана Ахмеда при вторичной рубеозной глаукоме. Глаукома: реальность и перспективы. Сб. науч. статей. Москва; 2008. [Lipatov DV, ChistjakovTA. Ispol’zovanie klapana Ahmeda pri vtorichnoj rubeoznoj glaukome. Glaukoma: real’nost’ i perspektivy. Sbornik nauchyh. statey. Moscow; 2008. (In Russ)].

9. Sivak-Callcott JA, O’Day DM, Gass JDM, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology.2001;108(10):1767-1776. doi: 10.1016/S0161-6420(01)00775-8

10. Netland PA, Ishida K, Boyle JW. The Ahmed Glaucoma Valve in patients with and without neovascular glaucoma. J Glaucoma. 2010;19(9):581-586. doi: 10.1097/IJG.0b013e3181ca7f7f

11. Бикбов М.М., Суркова В.К., Хуснитдинов И.И., и др. Результаты применения дренажа Ahmed при рефрактерной глаукоме. // Клиническая офтальмология. – 2013. – Т. ١٤. – №3 – С. 98-100.[Bikbov MM, Surkova VK, Khusnitdinov II, et al. Results of implantation of drenaige system Ahmed in patients with refractory glaucoma. Klinicheskaja oftal’mologija. 2013;14(3):98-100. (In Russ)].

12. Бикбов М.М., Суркова В.К., Хуснитдинов И.И., и др. Результаты хирургического лечения рефрактерной глаукомы с использованием коллагенового биодренажа. // Офтальмология. – 2014. – Т. 11. – №2 – С. 55-58. [Bikbov MM, Surkova VK, Orenburkina OI, et al. The outcomes of refractory glaucoma surgery using collagen bio-implant. Ophthalmology. 2014;11(2):55-58. (In Russ)].

13. Coleman AL, Hill R, Wilson MR, et al. Initial Clinical Experience With the Ahmed Glaucoma Valve Implant. Am J Ophthalmol. 1995;120(1):23-31. doi: 10.1016/s0002-9394(14)73755-9

14. Слонимский А.Ю., Алексеев И.Б., Долгий С.С., и др. Новый биодеградируемый дренаж «Глаутекс» в хирургическом лечении глаукомы // Национальный журнал глаукома. — 2012. — №4 — С. 55-59. [Slonimskij AU, Alekseev IB, Dolgij SS, et al. New biodegradable drainage “Glautex” in the surgical treatment of glaucoma. Natsional’nyi zhurnal glaucoma. 2012;(4):55-59. (In Russ)].

15. Eid TM, Radwan A, el-Manawy W, el-Hawary I. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol. 2009;44(4):451-456. doi: 10.3129/i09-108

16. Zhou M, Xu X, Zhang X, Sun X. Clinical Outcomes of Ahmed Glaucoma Valve Implantation With or Without Intravitreal Bevacizumab Pretreatment for Neovascular Glaucoma: A Systematic Review and Meta-Analysis. J Glaucoma. 2016;25(7):551-557. doi: 10.1097/IJG.0000000000000241

17. Sahyoun M, Azar G, Khoueir Z, et al. Long-term results of Ahmed glaucoma valve in association with intravitreal bevacizumab in neovascular glaucoma. J Glaucoma. 2015;24(5):383-388. doi: 10.1097/IJG.0000000000000234

18. Zhou M, Wang W, Huang W, et al. Adjunctive with versus without intravitreal bevacizumab injection before Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma. Chin Med J (Engl). 2013;126(8):1412-1417.

19. Topouzis F, Coleman AL, Choplin N, et al. Follow-up of the original cohort with the Ahmed glaucoma valve implant11The views expressed herein are those of the authors and are not the official opinions of the Department of the Navy, the Department of Defense, or the United States Government. Am J Ophthalmol. 1999;128(2):198-204. doi: 10.1016/s0002-9394(99)00080-x

20. Budenz DL, Barton K, Feuer WJ, et al. Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. Ophthalmology. 2011;118(3):443-452. doi: 10.1016/j.ophtha.2010.07.016